Compare G & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | G | AMRX |
|---|---|---|
| Founded | 1997 | 2002 |
| Country | Bermuda | United States |
| Employees | 140000 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.4B |
| IPO Year | 2007 | 2018 |
| Metric | G | AMRX |
|---|---|---|
| Price | $39.45 | $21.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $42.91 | $23.43 |
| AVG Volume (30 Days) | 1.7M | ★ 3.1M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.93% | N/A |
| EPS Growth | 9.82 | ★ 157.89 |
| EPS | ★ 1.71 | 0.37 |
| Revenue | ★ $2,279,438,000.00 | N/A |
| Revenue This Year | $7.02 | $4.73 |
| Revenue Next Year | $7.08 | $9.36 |
| P/E Ratio | ★ $22.68 | $57.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.85 | $10.68 |
| 52 Week High | $48.64 | $21.68 |
| Indicator | G | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.79 | 66.49 |
| Support Level | $32.99 | $16.59 |
| Resistance Level | $41.84 | N/A |
| Average True Range (ATR) | 1.24 | 0.61 |
| MACD | 0.15 | 0.12 |
| Stochastic Oscillator | 65.31 | 88.95 |
Genpact Ltd is an agentic, technology-solutions company offering digital transformation, data-driven operations, and technology-enabled services across multiple industries. Its core business services include decision support services; technology services like application lifecycle management, platform customization, and support, etc; and digital operations optimizing business processes. Genpact also offers data engineering, data management, and domain-based AI and generative AI solutions; develops new technology solutions for clients; and offers agentic solutions and technology consulting services. Its reportable segments are: High Tech and Manufacturing, which generate maximum revenue, Financial Services, and Consumer and Healthcare. Geographically, it derives maximum revenue from India.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.